Cargando…

Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease

BACKGROUND AND AIMS: The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature relating to microbial drug metabolism of medication prescribed in inflammatory bowel disease [IBD] practice. METHODS: A sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Crouwel, Femke, Buiter, Hans J C, de Boer, Nanne K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904070/
https://www.ncbi.nlm.nih.gov/pubmed/32652007
http://dx.doi.org/10.1093/ecco-jcc/jjaa143
_version_ 1783654856866660352
author Crouwel, Femke
Buiter, Hans J C
de Boer, Nanne K
author_facet Crouwel, Femke
Buiter, Hans J C
de Boer, Nanne K
author_sort Crouwel, Femke
collection PubMed
description BACKGROUND AND AIMS: The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature relating to microbial drug metabolism of medication prescribed in inflammatory bowel disease [IBD] practice. METHODS: A systematic literature search was performed in Embase and PubMed from inception to October 2019. The search was conducted with predefined MeSH/Emtree and text terms. All studies regarding drug metabolism by microbiota of medication prescribed in IBD practice were eligible. A total of 1018 records were encountered and 89 articles were selected for full text reading. RESULTS: Intestinal bacterial metabolism or modulation is of influence in four specific drugs used in IBD (mesalazines, methotrexate, glucocorticoids and thioguanine). The gut microbiota cleaves the azo-bond of sulfasalazine, balsalazide and olsalazine and releases the active moiety 5-aminosalicylic acid. It has an impact on the metabolization and potentially on the response of methotrexate therapy. In particular, thioguanine can be converted by intestinal bacteria into the pharmacologically active 6-thioguanine nucleotides without the requirement of host metabolism. Glucocorticoid compounds can be prone to bacterial degradation. CONCLUSION: The human intestinal microbiota can have a major impact on drug metabolism and efficacy of medication prescribed in IBD practice. A better understanding of these interactions between microbiota and drugs is needed and should be an integral part of the drug development pathway of new IBD medication.
format Online
Article
Text
id pubmed-7904070
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79040702021-03-01 Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease Crouwel, Femke Buiter, Hans J C de Boer, Nanne K J Crohns Colitis Review Articles BACKGROUND AND AIMS: The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature relating to microbial drug metabolism of medication prescribed in inflammatory bowel disease [IBD] practice. METHODS: A systematic literature search was performed in Embase and PubMed from inception to October 2019. The search was conducted with predefined MeSH/Emtree and text terms. All studies regarding drug metabolism by microbiota of medication prescribed in IBD practice were eligible. A total of 1018 records were encountered and 89 articles were selected for full text reading. RESULTS: Intestinal bacterial metabolism or modulation is of influence in four specific drugs used in IBD (mesalazines, methotrexate, glucocorticoids and thioguanine). The gut microbiota cleaves the azo-bond of sulfasalazine, balsalazide and olsalazine and releases the active moiety 5-aminosalicylic acid. It has an impact on the metabolization and potentially on the response of methotrexate therapy. In particular, thioguanine can be converted by intestinal bacteria into the pharmacologically active 6-thioguanine nucleotides without the requirement of host metabolism. Glucocorticoid compounds can be prone to bacterial degradation. CONCLUSION: The human intestinal microbiota can have a major impact on drug metabolism and efficacy of medication prescribed in IBD practice. A better understanding of these interactions between microbiota and drugs is needed and should be an integral part of the drug development pathway of new IBD medication. Oxford University Press 2020-07-11 /pmc/articles/PMC7904070/ /pubmed/32652007 http://dx.doi.org/10.1093/ecco-jcc/jjaa143 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review Articles
Crouwel, Femke
Buiter, Hans J C
de Boer, Nanne K
Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
title Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
title_full Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
title_fullStr Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
title_full_unstemmed Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
title_short Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease
title_sort gut microbiota-driven drug metabolism in inflammatory bowel disease
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904070/
https://www.ncbi.nlm.nih.gov/pubmed/32652007
http://dx.doi.org/10.1093/ecco-jcc/jjaa143
work_keys_str_mv AT crouwelfemke gutmicrobiotadrivendrugmetabolismininflammatoryboweldisease
AT buiterhansjc gutmicrobiotadrivendrugmetabolismininflammatoryboweldisease
AT deboernannek gutmicrobiotadrivendrugmetabolismininflammatoryboweldisease